Key Points {#FPar1}
==========

Intramuscular clodronate is well-tolerated and effective for the management of symptomatic knee osteoarthritis.The efficacy of clodronate is directly proportional to the treatment duration.

Introduction {#Sec1}
============

Osteoarthritis (OA) is highly prevalent worldwide and usually causes severe pain and disability \[[@CR1]\]. Since the early pathogenesis of the disease remains unknown, no drugs are yet available to stop the progression of OA. However, it is important that treatments to control pain and improve both physical activity levels and quality of life for patients are developed.

The pathogenesis of pain in OA is also uncertain, but the extensive use of magnetic resonance imaging (MRI) over recent decades has enabled researchers to understand some important points. The radiological detection of bone marrow edema (BME) in symptomatic joints and its correlation with OA development was an important step in understanding the progression of the disease \[[@CR2]--[@CR4]\].

Since an altered signal pattern seems related to lymphocytic infiltrates, fibrosis, increased vascularization, less mineralized bone, and real local edema, the preferred term in most recent literature OA is bone marrow lesions (BML).

However, more recent studies found some important correlations between BML and progression of pain and OA. Indeed, all histopathological studies have involved patients with severe joint disease, in whom the only therapeutic option was a prosthesis \[[@CR4]--[@CR7]\].

In recent years, bisphosphonates have proven their efficacy in the treatment of some diseases with a finding of BML and BME, especially at high dosages and with parenteral administration. However, continuous administration of bisphosphonates, even at lower dosages, has proven to have symptomatic effectiveness \[[@CR8]--[@CR11]\].

Clodronate is a nitrogen-free bisphosphonate that is widely and effectively used in the treatment of many osteo-metabolic disorders \[[@CR12]--[@CR16]\]. In particular, we highlight its efficacy in the treatment of algodystrophic syndrome \[[@CR17]\], hand-erosive OA \[[@CR18]\], and knee OA (intra-articular clodronate) \[[@CR19]\].

The aim of our study was to evaluate the efficacy of two therapeutic regimens of intramuscular clodronate, using identical initial therapeutic doses but different maintenance doses. The initial therapeutic dose was the same as used by Varenna et al. \[[@CR17]\] (intravenous clodronate 300 mg daily for 10 days) for the treatment of algodystrophy.

The safety of our proposed regimen was evidenced by the overall low incidence of adverse events during clodronate treatment \[[@CR20]\] and by the safety reported by Frediani et al. \[[@CR21]\], who used intramuscular clodronate 100 mg once or twice weekly in the treatment of postmenopausal osteoporosis.

Materials and Methods {#Sec2}
=====================

We included all patients who attended the Rheumatology Department of Policlinico Le Scotte, Siena, Italy, for knee pain from January 2013 to December 2014 who were aged \> 40 years and met the following inclusion criteria: knee OA according to American College of Rheumatology criteria \[[@CR22]\], Kellgren--Lawrence radiographic score ≥ 2 in the tibiofemoral joint \[[@CR23]\], worsening chronic knee pain lasting from 2 weeks to 43 months, visual analogue scale (VAS) \> 40/100 mm, BML diameter \> 0.5 cm as seen in a knee MRI, and lumbar or femoral T-score less than -2.5.

The main outcome of the study was variations in pain intensity using a VAS score. VAS score was recorded at baseline (T0) and after 30 days (T1), 3 months (T2), 6 months (T3), 9 months (T4), and 12 months (end of study; T5). As secondary endpoints, we evaluated functional status (Western Ontario and McMaster University Osteoarthritis Index \[WOMAC\] questionnaire---pain, stiffness and physical function---at T0, T1, T2, T3, T4, and T5), patient use of paracetamol (T0, T1, T2, T3, T4, and T5), and Whole Organ Magnetic Resonance Imaging Score (WORMS) modifications (T0, T2, and T5).

The exclusion criteria were hypocalcemia; hypercalcemia; low glomerular filtration rate (\< 30 mL/min); liver, kidney, heart, lung, or neurological diseases; diabetes; tumors; previous treatment with bisphosphonates; and knee pain due to trauma.

Intra-articular injection of steroids and/or hyaluronic acid was not permitted during the study or in the 3 months before.

During the study, patients were not permitted to use nonsteroidal anti-inflammatory drugs but were allowed to take paracetamol up to 3 g daily and were required to record consumption in their own diary. Paracetamol consumption was expressed in average grams per patient per day.

All procedures that involved human participants were in accordance with the ethical standards of the national and Hospital of Siena research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written consent to participate in the study.

Randomization {#Sec3}
-------------

Patients were randomized into two parallel treatment groups: Group 1 received intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 11.5 months; group 2 received intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 2.5 months.

Knee Magnetic Resonance Imaging {#Sec4}
-------------------------------

Each patient underwent 3-D high-resolution MRI at T0, T2, and T5. Every MRI was evaluated by an expert musculoskeletal radiologist blinded to patient grouping. The images were acquired in coronal, axial, and sagittal planes, with a field of view of 18 cm and 256 × 256 matrix, with an 0.5 mm intersection gap.

T1-weighted spin-echo MRI scans were acquired in coronal, axial, and sagittal planes (repetition time \[TR\] 580 ms, echo time \[TE\] 12 ms); T2-weighted spin-echo scans were acquired in axial and sagittal planes (TR 4000 ms, TE 30/100 ms); proton-density fat-suppression-weighted scans were acquired in a coronal plane (TR 2800 ms, TE 40 ms).

Subchondral BMLs were identified as high-intensity signal areas on T2-weighted fat-suppression imaging and analyzed using WORMS \[[@CR24]\].

BMLs were codified from 0 to 3 in each of the ten subregions of the medial and lateral tibiofemoral compartment and in each of the four subregions of the patellofemoral compartment by an experienced radiologist. The extent of lesions was evaluated using the WORMS scale (0 = no edema; 1 = \< 25%; 2 = 25--50%; 3 = \> 50%), and a total WORMS was calculated by adding the score for each subregion together.

Statistical Analysis {#Sec5}
--------------------

We computed the statistical significance using a two-tailed test, with a significance level set at \< 0.05.

According to the results of previous studies of pain reduction in patients treated with zoledronate \[[@CR25]\] and neridronate \[[@CR26]\], we anticipated a VAS score reduction of \> 20 mm in patients treated with clodronate.

We analyzed results according to the "intention-to-treat" principle, including all randomized patients who received at least one dose of clodronate. Since our outcomes were not normally distributed (Shapiro--Wilk test), we used nonparametric tests.

We used the Mann--Whitney *U* test to evaluate differences between the two groups and the Wilcoxon-signed rank test to evaluate the intra-group differences and WORMS score at T1, T2, T3, T4, and T5.

Predictive factors for VAS and WORMS modifications were evaluated using univariate and multivariate regression analysis.

We analyzed both absolute and percentage differences. All statistical tests were bilateral, with *p* \< 0.05, and evaluated using SPSS software (version 17.0; IBM, Armonk, NY, USA).

Results {#Sec6}
=======

A total of 74 patients were included in the study, equally distributed between the two groups. No patient withdrew before the end of the study. The two groups were similar at T0 (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristics at baseline (T0)CharacteristicsGroup 1 (*n* = 37)Group 2 (*n* = 37)*p* valueAge (years)68.3 ± 13.766.1 ± 12.10.2Sex (F/M), *n*24/1320/170.5BMI, kg/m^2^26.326.80.8Duration of pain, weeks12.7 ± 4.211.1 ± 3.50.1VAS score (0--100), mm62.4 ± 13.668.7 ± 17.30.2WOMAC score (pain)6.6 ± 2.07.2 ± 2.40.1WOMAC score (disability)20.6 ± 3.822.1 ± 4.30.3WOMAC score (stiffness)3.0 ± 1.52.9 ± 1.90.9WORMS6.9 ± 2.67.6 ± 3.70.2Data are presented as mean ± standard deviation or *N* (%) unless otherwise indicated. Group 1: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 11.5 months; group 2: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 2.5 months*BMI* body mass index, *F* female, *M* male, *VAS* visual analog scale, *WOMAC* Western Ontario and McMaster University Osteoarthritis Index, *WORMS* whole organ magnetic resonance imaging score

For both groups, VAS statistically significantly reduced until 3 months (T2), from 62.4 ± 13.6 (standard deviation) to 10.3 ± 8.9 in group 1 and from 68.7 ± 17.3 to 11.2 ± 9.4 in group 2. Group 1 then experienced a further VAS reduction at T3 (9.3 ± 7.8), with minimal changes at T4 (12.4 ± 8.7) and T5 (15.6 ± 9.8), whereas VAS scores for group 2 progressively increased (28.8 ± 20.3 at T3; 43.8 ± 30.1 at T4; 50.3 ± 31.9 at T5) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1VAS variation (%). *VAS* visual analog scale

The same trend was also observed for WOMAC score (pain, stiffness, physical function) (Table [2](#Tab2){ref-type="table"}).Table 2Patient characteristics at different timepoints during the studyCharacteristicsT0 (baseline)T1 (30 days)T2 (3 months)T3 (6 months)T4 (9 months)T5 (end of study; 12 months)Group 1Group 2Group 1Group 2Group 1Group 2Group 1Group 2Group 1Group 2Group 1Group 2VAS62.4 ± 13.668.7 ± 17.335.2\* ± 11.237.8\* ± 13.110.3\* ± 8.911.2\* ± 9.49.3\* ± 7.828.3\*\* ± 10.3^††^12.4\* ± 8.743.8^†^ ± 30.115.6\* ± 9.850.3^†^ ± 31.9WOMAC pain6.6 ± 2.07.2 ± 2.44.1\*\* ± 0.94.3\*\* ± 0.72.8\* ± 0.72.3\* ± 0.92.5\* ± 1.03.8\*\* ± 1.9^††^3.0\* ± 1.45.2 ± 3.8^††^2.8\* ± 1.25.8 ± 4.1^†^WOMAC disability20.6 ± 3.822.1 ± 4.315.1\*\* ± 4.317.2\*\* ± 5.210.2\* ± 4.310.8\* ± 5.012.1\* ± 4.818.1^††^ ± 6.913.2\* ± 5.220.3^††^ ± 9.913.5\* ± 5.724.0 ± 11.9^†^WOMAC stiffness3.0 ± 1.52.9 ± 1.92.0\*\* ± 1.22.2\*\* ± 1.31.3\* ± 0.91.4\* ± 0.71.4\* ± 0.92.0\*\* ± 1.91.5\* ± 1.12.8^†^ ± 2.11.7\* ± 1.33.2^†^ ± 2.7WORMS6.9 ± 2.67.6 ± 3.7NANA2.1\* ± 1.82.0\* ± 1.2NANANANA1.1\* ± 0.85.9^†^ ± 4.9Data are presented as mean ± standard deviation. Group 1: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 11.5 months; group 2: intramuscular clodronate 200 mg daily for 15 days, then once weekly for the next 2.5 months*NA* not measured at this timepoint, *VAS* visual analog scale, *WOMAC* Western Ontario and McMaster University Osteoarthritis IndexT vs. T0: \**p* \< 0.01, \*\**p* \< 0.05; Group 1 vs. group 2: ^†^*p* \< 0.01; ^††^*p* \< 0.05

The consumption of paracetamol decreased in both groups until T2 (group 1: 1.16 ± 0.6 at T0; 0.72 ± 0.5 at T1; 0.55 ± 0.5 at T2; group 2: 1.13 ± 0.6 at T0; 0.72 ± 0.4 at T1; 0.64 ± 0.4 at T2). The average intake of paracetamol increased in group 2 (0.94 ± 0.6 at T3; 1.04 ± 0.7 at T4; 1.05 ± 0.7 at T5) but further reduced in group 1 at T3 and T4 (0.42 ± 0.4 and 0.28 ± 0.2, respectively), remaining substantially stable at T5 (0.29 ± 0.2).

BML extension, evaluated by WORMS total score, progressively decreased (group 1: 6.9 ± 2.6 at T0 to 2.1 ± 1.8 at T2; group 2: 7.6 ± 3.7 at T0 to 2.0 ± 1.2 at T2) (Fig. [3](#Fig3){ref-type="fig"}); in group 1, it continued to decrease until T5 (1.1 ± 0.8), whereas it increased in group 2 (5.9 ± 4.9 at T5) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2WORMS variation (%). *WORMS* Whole Organ Magnetic Resonance Imaging Score

No adverse events were reported during the study, as expected given the results reported by Frediani et al. \[[@CR21]\]. In particular, no difference in serum creatinine or creatinine clearance was found after 3, 6, 9, and 12 months of treatment (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3MRI before and after clodronate therapy (T2 \[3 months\]). *MRI* magnetic resonance imaging

Discussion {#Sec7}
==========

Bisphosphonates have proven effective in several conditions characterized by BME and pain, and clodronate in particular is well-known for its anti-inflammatory and analgesic properties \[[@CR8], [@CR18]--[@CR20]\] and good safety profile. Intravenous clodronate has proven effective against BME of algodystrophic syndrome when administered at a dose of 300 mg/day for 10 days \[[@CR17]\] and has been used to treat painful episodes of erosive OA of the hand \[[@CR18]\].

Another case report described the effectiveness of intramuscular clodronate 100 mg in ankle algodystrophic syndrome in a patient with psoriatic arthritis \[[@CR27]\].

More powerful molecules, such as amino-bisphosphonates, are widely described in the treatment of algodystrophic syndrome, namely neridronate \[[@CR28]\] and alendronate \[[@CR29]\]; however, their mechanism of action means they can cause well-known acute phase reactions, especially when administered intravenously.

Only a few papers describe the role of bisphosphonates in OA, with the vast majority investigating clodronate. The role of clodronate in OA, summarized in the recent review by Saviola et al. \[[@CR30]\], is an intriguing matter of debate: it may represent a promising therapy even in erosive OA \[[@CR31]\], in which it was found to be superior over hydroxychloroquine in reducing pain and loss of strength \[[@CR18]\]. Moreover, clodronate, the role of which in bone metabolism has been previously summarized and widely described, may also have a role in chondrocyte differentiation, as outlined by Valenti et al. \[[@CR32]\], who reported that nanoparticles of clodronate led to SOX9 upregulation. However, none of these studies evaluated the effect of clodronate on BML.

Two previous studies reported that the bisphosphonates neridronate \[[@CR26]\] and zoledronate \[[@CR25]\] were both effective in terms of reducing pain and physical impairment in knee OA, but neridronate appeared to have a faster onset of action and was better at reducing BML. However, further data on middle- and long-term efficacy are absent.

A strong correlation between BML and pain has been assumed, as pain can be caused by impaired venous drainage, increased intra-osseous pressure, and local acidosis \[[@CR33]\].

However, no consensus has been reached on what exactly defines a BML from a histopathologic viewpoint. According to the most recent literature, an altered signal pattern appears to be related to lymphocytic infiltrates, fibrosis, increased vascularization, and less mineralized bone, as well as real local edema \[[@CR34]\]; trabecular bone is also involved, and bony remodeling is a common finding \[[@CR35]\].

Bisphosphonates are well-known to have both central and peripheral anti-inflammatory and analgesic effects. Interesting applications of bisphosphonates include studies in animal models of collagen-induced arthrosis, where rational use of the antiresorptive drug is described in recent scientific literature emphasizing the role of osteoclastic activation by pro-inflammatory cytokines in the genesis of structural bone damage and erosions. Inhibition of bone resorption, from this viewpoint, is a key point in arthritis therapy \[[@CR36], [@CR37]\].

However, in animal models, amino-bisphosphonates exacerbated joint inflammation \[[@CR38]\], despite their positive effects on structural bone damage, whereas clodronate had positive effects on inhibition of both structural damage and joint inflammation \[[@CR39], [@CR40]\].

In particular, Bonabello's studies \[[@CR41], [@CR42]\] in animal models highlighted a pain-relieving and antinociceptive effect of clodronate at both central and peripheral levels, independent of the antifracture effect. Several reports have highlighted the pain-relieving properties of clodronate in different fields \[[@CR43]--[@CR48]\]. Clodronate's analgesic effect is known and commonly used in clinical practice, including in patients with vertebral fragility fractures \[[@CR43]--[@CR45]\], where the drug had a greater pain-killing effect than other amino-bisphosphonates, including neridronate \[[@CR46]\]. In addition, we cannot forget the analgesic role of clodronate in oncology, especially in patients with skeletal involvement \[[@CR47], [@CR48]\].

Moreover, a recent randomized controlled trial proved the effectiveness of intra-articular clodronate 2 mg per week for 4 weeks in reducing pain compared with NaCl 0.9% \[[@CR19]\]; the same working group proved the noninferiority of intra-articular clodronate versus hyaluronic acid \[[@CR49]\].

As reported in studies using zoledronate \[[@CR25]\] and neridronate \[[@CR26]\] in OA, our paper indicates that clodronate reduces pain and BML. Our study is also the first to demonstrate that an initial higher dose of clodronate followed by intramuscular maintenance administration prevented increased BML and pain; patients who stopped treatment did not experience this effect.

Our study has a limitation that should be noted: We used indirect instruments for the evaluation of drug efficacy, such as a pain questionnaire and WORMS. This score measures the extent of edema, but we acknowledge that edema may be related not only to OA but also to many other conditions (trauma, inflammation, and tumor, among others).

Conclusions {#Sec8}
===========

Intramuscular clodronate at a therapeutic dose followed by a maintenance dose is effective in the management of symptomatic knee OA, improving functional outcomes and reducing pain and BML.

Further studies are needed to create a universal treatment schedule for the use of clodronate in this complex disease. In particular, clodronate may offer enhanced protection in early-stage OA, so should be investigated in such patients.

Higher doses of this drug than used in osteoporosis will be necessary, and the duration will need to be longer than that used in algodystrophic syndrome.
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